What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Daniel D. Von Hoff mostly deals with Internal medicine, Oncology, Cancer, Cancer research and Pharmacology.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery.
His study on Cancer research also encompasses disciplines like
- Gene and related Molecular biology,
- Endocrinology that connect with fields like Vismodegib.
In his research, Human tumor is intimately related to In vivo, which falls under the overarching field of Pharmacology.
The Gemcitabine study combines topics in areas such as Paclitaxel, Pancreatic cancer, Phases of clinical research and Hazard ratio.
His Pharmacokinetics research includes elements of Chemotherapy and Docetaxel.
His most cited work include:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine (3192 citations)
- Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. (1148 citations)
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma (929 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Cancer, Cancer research, Oncology and Pancreatic cancer.
His study ties his expertise on Gastroenterology together with the subject of Internal medicine.
Daniel D. Von Hoff interconnects Tolerability and Bioinformatics in the investigation of issues within Cancer.
His research in Cancer research focuses on subjects like Pathology, which are connected to In vitro.
His Oncology research includes elements of Regimen and Clinical trial, Phases of clinical research.
His work deals with themes such as Tumor microenvironment, Endocrinology, Pancreas and Adenocarcinoma, which intersect with Pancreatic cancer.
He most often published in these fields:
- Internal medicine (40.16%)
- Cancer (26.67%)
- Cancer research (25.56%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (40.16%)
- Oncology (25.87%)
- Pancreatic cancer (22.54%)
In recent papers he was focusing on the following fields of study:
Daniel D. Von Hoff mainly focuses on Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Cancer.
As part of his studies on Internal medicine, Daniel D. Von Hoff often connects relevant areas like Gastroenterology.
In Oncology, Daniel D. Von Hoff works on issues like Adenocarcinoma, which are connected to Pathology.
His studies deal with areas such as Cancer research, Stromal cell, Survival rate, Pancreas and Cancer-Associated Fibroblasts as well as Pancreatic cancer.
His Gemcitabine research includes themes of Regimen and Fluorouracil.
His research on Cancer also deals with topics like
- Pharmacology that intertwine with fields like Docetaxel,
- Pharmacokinetics which intersects with area such as Nausea and Dosing.
Between 2013 and 2021, his most popular works were:
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial (481 citations)
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial (376 citations)
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type (295 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Cancer are his primary areas of study.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Pharmacology.
The study incorporates disciplines such as Clinical trial, Surgery, Toxicity, Hazard ratio and Breast cancer in addition to Oncology.
The concepts of his Pancreatic cancer study are interwoven with issues in Tumor microenvironment, Cancer research, Chemotherapy and Survival rate.
His Gemcitabine research is multidisciplinary, relying on both Clinical endpoint, Fluorouracil, Paclitaxel and Phases of clinical research.
His Cancer study combines topics from a wide range of disciplines, such as Immune system, Immunology, Activator and Doxorubicin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
